Afatinib (Giotrif®) : The 1st choice in 1st-line

Afatinib: The 1st line choice in sequential therapy of NSCLC

 
 

Robust TTF improvement and tumor response with first-line AFATINIB in most NSCLC patients with uncommon EGFR mutations

Document ID: PC-VN-101472

28/06/2021

Author: Boehringer Ingelheim

123,000
Views

100k 340

NHỮNG NỘI DUNG LIÊN QUAN

 
PC-VN-101472
Production date: June 2021